Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 4:34 PM
Ignite Modification Date: 2025-12-25 @ 2:26 PM
NCT ID: NCT03331666
Description: None
Frequency Threshold: 0
Time Frame: 4 months
Study: NCT03331666
Study Brief: Impact of LDL-cholesterol Lowering on Platelet Activation
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Evolocumab Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196. Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia 0 None 0 2 0 2 View
Placebo Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196. Evolocumab: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia 0 None 0 2 0 2 View
Serious Events(If Any):
Other Events(If Any):